Q3 Earnings Forecast for AVDL Issued By HC Wainwright

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Equities research analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Avadel Pharmaceuticals in a research report issued on Tuesday, March 4th. HC Wainwright analyst O. Livnat forecasts that the company will post earnings of $0.01 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Avadel Pharmaceuticals’ Q4 2025 earnings at $0.12 EPS.

A number of other research firms have also recently weighed in on AVDL. Piper Sandler reduced their price target on Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating for the company in a report on Friday, January 10th. Deutsche Bank Aktiengesellschaft started coverage on Avadel Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $12.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of Avadel Pharmaceuticals in a report on Monday. Finally, UBS Group reduced their target price on Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating for the company in a report on Monday, January 13th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Avadel Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $19.88.

Avadel Pharmaceuticals Stock Up 3.0 %

Shares of AVDL stock opened at $7.87 on Thursday. The stock has a market cap of $758.37 million, a PE ratio of -9.96 and a beta of 1.28. The business has a 50-day simple moving average of $8.72 and a 200-day simple moving average of $11.48. Avadel Pharmaceuticals has a 52-week low of $7.39 and a 52-week high of $19.09.

Insider Buying and Selling

In other Avadel Pharmaceuticals news, CFO Thomas S. Mchugh purchased 5,000 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were bought at an average cost of $10.49 per share, for a total transaction of $52,450.00. Following the completion of the purchase, the chief financial officer now directly owns 85,500 shares in the company, valued at approximately $896,895. This represents a 6.21 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Gregory J. Divis purchased 9,598 shares of the business’s stock in a transaction on Friday, December 6th. The stock was acquired at an average price of $9.98 per share, for a total transaction of $95,788.04. Following the completion of the purchase, the chief executive officer now owns 9,598 shares of the company’s stock, valued at $95,788.04. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 55,579 shares of company stock worth $526,363. Company insiders own 4.80% of the company’s stock.

Institutional Trading of Avadel Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC purchased a new position in shares of Avadel Pharmaceuticals during the third quarter worth about $31,000. Advisors Asset Management Inc. grew its holdings in shares of Avadel Pharmaceuticals by 56.1% during the third quarter. Advisors Asset Management Inc. now owns 7,921 shares of the company’s stock worth $104,000 after purchasing an additional 2,846 shares during the last quarter. Hsbc Holdings PLC purchased a new position in shares of Avadel Pharmaceuticals during the fourth quarter worth about $113,000. Kazazian Asset Management LLC purchased a new position in shares of Avadel Pharmaceuticals during the fourth quarter worth about $126,000. Finally, Sanctuary Advisors LLC purchased a new position in shares of Avadel Pharmaceuticals during the fourth quarter worth about $140,000. 69.19% of the stock is currently owned by institutional investors and hedge funds.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.